MiNK Therapeutics, Inc. financial data

Symbol
INKT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
149 Fifth Avenue, Suite 500, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
AgenTus Therapeutics, Inc. (to 3/18/2021), AgenTus Therapeutics, Inc. (to 3/18/2021)
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 59.3 % -55.3%
Return On Equity 99.8 % -92.7%
Return On Assets -234 % -69.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.5M shares +14.6%
Common Stock, Shares, Outstanding 34.6M shares +2.19%
Entity Public Float 20.5M USD +211%
Common Stock, Value, Issued 394 USD +14.2%
Weighted Average Number of Shares Outstanding, Basic 37.1M shares +7.94%
Weighted Average Number of Shares Outstanding, Diluted 37.1M shares +7.94%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.1M USD -46.3%
General and Administrative Expense 6.33M USD -14%
Operating Income (Loss) -17.6M USD +37.2%
Net Income (Loss) Attributable to Parent -17.1M USD +34.2%
Earnings Per Share, Basic -0.48 USD/shares +37.7%
Earnings Per Share, Diluted -0.48 USD/shares +37.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.31M USD -12.3%
Other Assets, Current 61.1K USD -63.2%
Assets, Current 9.47M USD -14.3%
Property, Plant and Equipment, Net 850K USD -19.7%
Assets 10.3M USD -14.8%
Accounts Payable, Current 3.2M USD -34.5%
Accrued Liabilities, Current 4.63M USD +8.87%
Liabilities, Current 10.1M USD -11.5%
Other Liabilities, Noncurrent 23.3K USD -70.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -611K USD -52.2%
Retained Earnings (Accumulated Deficit) -140M USD -13.9%
Stockholders' Equity Attributable to Parent -16.6M USD -74.6%
Liabilities and Equity 10.3M USD -14.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.54M USD +41.8%
Net Cash Provided by (Used in) Financing Activities 5.01M USD
Net Cash Provided by (Used in) Investing Activities -13.5K USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 39.4M shares +14.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.45M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.31M USD -12.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.12K USD -48.6%
Deferred Tax Assets, Valuation Allowance 29.7M USD +31%
Deferred Tax Assets, Gross 29.7M USD +31%
Depreciation 53.8K USD +17.8%
Payments to Acquire Property, Plant, and Equipment 13.5K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -17.3M USD +37.5%
Property, Plant and Equipment, Gross 1.45M USD +7.33%
Preferred Stock, Shares Authorized 5M shares
Share-based Payment Arrangement, Expense 3.58M USD +9.85%
Interest Expense 848K USD +14%